FDA Delays Review of Agios Sickle Cell Drug Mitapivat
The regulatory timeline for the therapy is extended to February 2027 while the agency evaluates potential safety measures.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize safety during the drug approval process?
The FDA has extended the review period for the Agios mitapivat supplemental New Drug Application (sNDA) for sickle cell disease by three months. The delay follows the agency's classification of the company's recent submission of nine months of updated safety data as a major amendment.
Why it matters
The extension allows the FDA to evaluate whether a Risk Evaluation and Mitigation Strategy (REMS) program is necessary for mitapivat to ensure safe use in patients. This regulatory step marks a critical hurdle for Agios in securing approval for a therapy designed to treat sickle cell disease.
The application update includes nine months of additional safety data from the RISE UP Phase 3 trial, which involves 207 participants. The FDA requested this information to assess potential safety protocols following initial reviews of the sNDA, which was submitted under the accelerated approval pathway.
The players
Agios
A Cambridge, Massachusetts-based biopharmaceutical company focused on developing small-molecule medicines for rare diseases.
FDA
The United States federal agency responsible for regulating new drug approvals and safety protocols.
The details
Mitapivat is a small-molecule drug designed to treat sickle cell disease, a condition affecting approximately 100,000 people in the U.S. The current review centers on potential Risk Evaluation and Mitigation Strategy (REMS) requirements, which are FDA-mandated programs used to manage known or potential serious risks associated with a drug. Agios submitted updated data from its Phase 2 and Phase 3 trials to address the agency's specific questions regarding these safety evaluations.
Timeline
July 2026: Agios dosed the first patient in the confirmatory REIGNITE trial.
October 9, 2026: The FDA requested additional information regarding a potential REMS.
October 19, 2026: Agios submitted a response to the FDA information request.
October 28, 2026: The FDA classified the company's response as a major amendment.
February 1, 2027: The new PDUFA goal date for the mitapivat sNDA.
The Tech Race
The mitapivat application is being evaluated under the FDA accelerated approval pathway, which allows for earlier market entry based on surrogate endpoints. The current review process is a critical checkpoint that follows the initiation of the company's confirmatory REIGNITE Phase 3 trial.
Patients and clinicians awaiting new therapies for sickle cell disease must wait an additional three months for the regulatory outcome. The availability of mitapivat remains contingent on the final approval and any associated risk management requirements determined by the FDA.
The takeaway
The three-month delay underscores the regulatory rigor required for sickle cell disease treatments currently moving through the pipeline. Stakeholders should track the February 1, 2027, PDUFA date for the final decision on approval and label requirements.
What happens next
The FDA is scheduled to reach a final decision on the mitapivat application by the new PDUFA goal date of February 1, 2027.
Further reading
For broader insights into drug development, see Biotech.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that pharmaceutical companies prioritize safety during the drug approval process?
